3 results
Primary ObjectivesTo assess the safety of 2 fixed doses of EVP-6124 (2 or 3 mg daily) for up to 52 weeks in subjects withAlzheimer*s disease (AD) who complete (Day 182) studies EVP-6124-024 or EVP-6124-025Secondary ObjectivesTo assess the duration…
Primary Objective: to determine the status of screw degradation, osseous replacement and host response of a biodegradable self-reinforcedTM poly 96L/4D lactide copolymer and βTCP biocomposite interference screw at five years after an ACL…
To compare the efficacy of a fixed dose of SC methylnaltrexone to induce laxation in patients receiving palliative care with constipation due to either fentanyl, oxycodone or morphine sulphate (opioids with different mechanisms of action). Secondary…